The extended lipid panel assay: a clinically-deployed high-throughput nuclear magnetic resonance method for the simultaneous measurement of lipids and Apolipoprotein B
Tóm tắt
Standard lipid panel assays employing chemical/enzymatic methods measure total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C), from which are calculated estimates of low-density lipoprotein cholesterol (LDL-C). These lipid measures are used universally to guide management of atherosclerotic cardiovascular disease risk. Apolipoprotein B (apoB) is generally acknowledged to be superior to LDL-C for lipid-lowering therapeutic decision-making, but apoB immunoassays are performed relatively infrequently due to the added analytic cost. The aim of this study was to develop and validate the performance of a rapid, high-throughput, reagent-less assay producing an “Extended Lipid Panel” (ELP) that includes apoB, using the Vantera® nuclear magnetic resonance (NMR) analyzer platform already deployed clinically for lipoprotein particle and other testing. Partial least squares regression models, using as input a defined region of proton NMR spectra of plasma or serum, were created to simultaneously quantify TC, TG, HDL-C, and apoB. Large training sets (n > ~ 1000) of patient sera analyzed independently for lipids and apoB by chemical methods were employed to ensure prediction models reflect the wide lipid compositional diversity of the population. The analytical performance of the NMR ELP assay was comprehensively evaluated. Excellent agreement was demonstrated between chemically-measured and ELP assay values of TC, TG, HDL-C and apoB with correlation coefficients ranging from 0.980 to 0.997. Within-run precision studies measured using low, medium, and high level serum pools gave coefficients of variation for the 4 analytes ranging from 1.0 to 3.8% for the low, 1.0 to 1.7% for the medium, and 0.9 to 1.3% for the high pools. Corresponding values for within-lab precision over 20 days were 1.4 to 3.6%, 1.2 to 2.3%, and 1.0 to 1.9%, respectively. Independent testing at three sites over 5 days produced highly consistent assay results. No major interference was observed from 38 endogenous or exogenous substances tested. Extensive assay performance evaluations validate that the NMR ELP assay is efficient, robust, and substantially equivalent to standard chemistry assays for the clinical measurement of lipids and apoB. Routine reporting of apoB alongside standard lipid measures could facilitate more widespread utilization of apoB for clinical decision-making.
Tài liệu tham khảo
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139:e1082–143.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205.
Nordestgaard BG, Langlois MR, Langsted A, Chapman MJ, Aakre KM, Baum H, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Atherosclerosis. 2020;294:46–61.
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. Americvan Association of Clinical Endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1–87.
Clinical Laboratory Fee Schedule File 20CLABQ3. U.S. Centers for Medicare & Medicaid Services, Baltimore. 2020. https://www.cms.gov/httpswwwcmsgovmedicaremedicare-fee-for-service-paymentclinicallabfeeschedclinical-laboratory-fee/20clabq3. Accessed 11 Sept 2020.
Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847–70.
Matyus SP, Braun PJ, Wolak-Dinsmore J, Jeyarajah EJ, Shalaurova I, Xu Y, et al. NMR measurement of LDL particle number using the Vantera clinical analyzer. Clin Biochem. 2014;47:203–10.
Matyus SP, Braun PJ, Wolak-Dinsmore J, Saenger AK, Jeyarajah EJ, Shalaurova I, et al. HDL particle number measured on the Vantera®, the first clinical NMR analyzer. Clin Biochem. 2015;48:148–55.
Shalaurova I, Connelly MA, Garvey WT, Otvos JD. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab Syndr Rel Disord. 2014;12:422–9.
Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, Tracy RP. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem. 2015;61:714–23.
Wolak-Dinsmore J, Gruppen EG, Shalaurova I, Matyus SP, Grant RP, Gegen R, et al. A novel NMR-based assay to measure circulating concentrations of branched-chain amino acids: elevation in subjects with type 2 diabetes mellitus and association with carotid intima media thickness. Clin Biochem. 2018;54:92–9.
Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics. Chemom Intell Lab Syst. 2001;58:109–30.
Bathan TF, Krane J, Engan T, Bjerve K, Axelson D. Quantification of plasma lipids and apolipoproteins by use of proton NMR spectroscopy, multivariate and neural network analysis. NMR Biomed. 2000;13:271–88.
Dyrby M, Petersen M, Whittaker AK, Lambert L, Nørgaard L, Bro R, Engelsen SB. Analysis of lipoproteins using 2D diffusion-edited NMR spectroscopy and multi-way chemometrics. Anal Chim Acta. 2005;531:209–16.
Arlot A. A survey of cross-validation procedures for model selection. Stat Surv. 2010;4:40–79.
Montgomery DC, Peck E, Vining GG. Introduction to linear regression analysis. 5th ed. Hoboken: Wiley, Inc; 2012.
Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol. 2020;5:540–8.
CLSI Document EP17-a. Protocols for determination of limits of detection and limits of quantitation; approved guideline. Wayne, PA USA: Clinical and Laboratory Standards Institute; 2004.
CLSI Document EP6-a. Evaluation of the linearity of quantitative measurement procedures: a statistical approach. Wayne, PA: Clinical and Laboratory Standards Institute; 2003.
CLSI Document EP5-A2. Evaluation of precision performance of quantitative measurements methods; approved guideline-second edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2004.
CLSI Document EP9-A2. Method comparison and Bias estimation using patient samples; approved guideline-second edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2002.
CLSI Document EP9-A3. Measurement procedure comparison and Bias estimation using patient samples; approved guideline-third edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
CLSI Document EP7-A2. Interference testing in clinical chemistry; approved guideline-second edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
CLSI document EP14-A2. Evaluation of Matrix Effects; Approved Guideline-Second Edition. Wayne: Clinical and Laboratory Standards Institute; 2005.
CLSI document EP14-A3. Evaluation of Cummutability of Processed Samples; Approved Guideline-Third Edition. Wayne: Clinical and Laboratory Standards Institute; 2014.
Mihaleva VV, van Schalkwijk DB, de Graaf AA, van Duynhoven J, van Dorsten FA, Vervoort J, et al. A systematic approach to obtain validated partial least square models for predicting lipoprotein subclasses from serum NMR spectra. Anal Chem. 2014;86:543–50.
Jimenez B, Holmes E, Heude C, Tolson RF, Harvey N, Lodge SL, et al. Quantitative lipoprotein subclass and low molecular weight metabolite analysis in human serum and plasma by 1H NMR spectroscopy in a multilaboratory trial. Anal Chem. 2018;90:11962–71.
Holmes MV, Millwood IY, Kartsonaki C, Hill MR, Bennett DA, Boxall R, et al. Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. J Am Coll Cardiol. 2018;71:620–32.
Delatour V, Clouet-Foraison N, Gaie-Levrel F, Marcovina SM, Hoofnagle AN, Kuklenyik Z, et al. Comparability of lipoprotein particle number concentrations across ES-DMA, NMR, LC-MS, Immunonephelometry, and VAP: in search of a candidate reference measurement procedure for apoB and non-HDL-P standardization. Clin Chem. 2018;64:1485–95.
Sniderman AD, Thanassoulis G, Navar AM, Pencina M, Catapano A, Ference BA. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4:1287–95.